Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 4

Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications

NCT00153127 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess treatment responses comparing a newly FDA-approved PEG laxative versus placebo.

Conditions Studied

Interventions

  • DRUG polyethyleneglycol3350

Study Locations (4)

Alabama

  • — Mobile

Florida

  • — St. Petersburg

Missouri

  • — St Louis

North Carolina

  • — Raleigh

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2001-11
Phase Phase 4

Sponsor

Braintree Laboratories

10 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00153127

The ClinicalTrials.gov registry entry for NCT00153127 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 10 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Constipation appearing as the primary indexed condition, and to 1 intervention — of which polyethyleneglycol3350 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00153127 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Alabama, Florida, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00153127 about?

NCT00153127 is a clinical study titled "Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications". The purpose of this study is to assess treatment responses comparing a newly FDA-approved PEG laxative versus placebo.

What is the current status of trial NCT00153127?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2001-11.

What conditions does trial NCT00153127 study?

This clinical trial studies the following conditions: Constipation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00153127?

The interventions under investigation include: polyethyleneglycol3350 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00153127?

This trial is sponsored by Braintree Laboratories, which has 10 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00153127 being conducted?

This trial has 4 study locations across Alabama, Florida, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial